Vanda Pharmaceuticals: Q2 Earnings Insights


Shares of Vanda Pharmaceuticals VNDA were flat in after-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share rose 6.25% year over year to $0.17, which beat the estimate of $0.14.

Revenue of $67,899,000 rose by 9.15% year over year, which missed the estimate of $69,750,000.


Vanda Pharmaceuticals Sees FY21 Revs $270M-$300M Vs $282.92M

Details Of The Call

Date: Jul 28, 2021

Time: 04:30 PM

ET Webcast URL:

Price Action

Company's 52-week high was at $21.86

Company's 52-week low was at $9.00

Price action over last quarter: Up 11.54%

Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improves the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt for the treatment of schizophrenia. Its other products include Tradipitant (VLY-686), VTR-297, and VQW-765.

Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!